TP53 and neoplasm: No significant relationship was found between immunostaining of p53 (cut-off 20%) and the clinicopathological variables, including age group (>50 years versus ≤50 years old), tumor grade (low versus high), or tumor stage (muscle-invasive versus non-invasive).